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Toxicity of AFB1 in Hepatocellular
Carcinoma
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Abstract
Our previous reports have shown that the genetic single-nucleotide polymor-
phisms (GSNPs) in the DNA repair gene X-ray repair cross complementing
4 (XRCC4) are involved in the carcinogenesis of hepatocellular carcinoma (HCC)
induced by aflatoxin B1 (AFB1). However, the effects of GSNPs in the coding
regions of XRCC4 on hepatic toxicity of AFB1 have been less investigated. We
conducted a hospital-based clinic tissue samples with pathologically diagnosed HCC
(n = 380) in a high AFB1 exposure area to explore the possible roles of GSNPs in
the coding regions of XRCC4 in AFB1-induced HCC using liver toxicity assays.
A total of 143 GSNPs were included in the present study and genotyped using the
SNaPshot method, whereas the liver toxicity of AFB1 was evaluated using AFB1-
DNA adducts in the tissues with HCC. In the clinicopathological samples with HCC,
the average adduct amount is 2.27  1.09 μmol/mol DNA. Among 143 GSNPs of
XRCC4, only rs1237462915, rs28383151, rs762419679, rs766287987, and rs3734091
significantly increased the levels of AFB1-DNA adducts. Furthermore, XRCC4
GSNPs (including rs28383151, rs766287987, and rs3734091) also increased
cumulative hazard for patients with HCC. These results suggest that the liver
toxicity of AFB1 may be modified by XRCC4 GSNPs.
Keywords: AFB1, liver toxicity, XRCC4, genetic single-nucleotide polymorphism,
hepatocellular carcinoma
1. Introduction
Aflatoxin B1 (AFB1) is an important type I chemical toxicant mainly produced
by the toxigenic strains of Aspergillus flavus (A. flavus) and Aspergillus parasiticus
(A. parasiticus) [1, 2]. This carcinogen is often taken into human body via contam-
inating human foods such as nuts and cereals and displays its toxic effects, espe-
cially hepatic toxicity [1–8]. AFB1-induced hepatic effects consist of acute toxic
damages (such as severe DNA damage, severe liver degeneration and necrosis, and
1
the failure of hepatic function) and chronic cumulative damages (such as a series of
cumulative DNA damage, slight hepatocellular degeneration and necrosis,
chronic inflammation, liver cirrhosis, and liver cancer) [3–5]. Increasing
evidence has shown that under the same exposure of AFB1, some individuals
feature severe hepatic damage; others have no noticeable damage [9–14]. This
suggests that different individuals have different responses to the toxic effects
of AFB1 and genetic factors may play a central role in the AFB1-induced
hepatic toxicity.
X-ray repair cross complementing 4 (XRCC4), an important DNA repair
gene involved in nonhomologous end-joining (NHEJ) repair pathway, plays a
scaffold function via stabilizing and localizing DNA repair enzymes LIG IV,
Ku70/80 heterodimer, and the DNA-dependent protein kinase (DNA-PK)
catalytic subunit (DNA-PKcs) in the ends of DNA double-stranded breaks
(DSBs) during NHEJ [15, 16]. In the past decades, growing reports have
exhibited that the abnormal structures and functions of XRCC4 may alter the
capacity of DNA repair and ultimately result in human diseases [17–22]. Several
recent studies have also shown that the genetic alterations in the coding regions
of XRCC4 can modify hepatocellular carcinoma (HCC) risk and prognosis
[23–27]. However, the effects of this genetic alteration on the hepatic toxicity of
AFB1 is unclear. Here, we conducted a clinical sample study exposure to explore
whether the genetic single-nucleotide polymorphisms (GSNPs, a type of genetic
alterations) in the coding regions of XRCC4 modified the effects of AFB1 on
hepatic damage.
2. Materials and methods
2.1 Study population
This was a hospital-based molecular epidemiological study conducted in high
AFB1 exposure area, Guangxi Zhuang Region, China. All participants were newly
diagnosed HCC cases and recruited from the Affiliated Hospitals of Youjiang
Medical University for Nationalities (located at Bose region, a major AFB1 exposure
area) between January 2010 and January 2013 inclusively. The inclusive criteria of
cases consisted of (a) cases with ultimately histopathologically confirmed HCC;
(b) cases without any evidence of hepatitis virus infection; (c) cases with the
history of AFB1 exposure which was defined according to positive history of
peripheral serum AFB1-albumin adducts [5, 24]; and (d) cases with available tumor
tissue samples and clinicopathological data.
According to the criteria, a total of 380 cases with HCC were recruited in this
study during the period. With informed consent, the tissue samples with HCC for
all patients and clinicopathological data were collected. Additionally, survival
follow-up information was also collected through cases themselves or their family
contact. In this study, the last follow-up date was set on January 31, 2019. The
protocol for clinical samples was approved by Youjiang Medical University for
Nationalities Medical Ethics Committee.
2.2 The evaluation of AFB1-related hepatic toxicity
Hepatic toxicity of AFB1 was evaluated using AFB1-DNA adducts in the tissue
samples with HCC, and the amounts of AFB1-DNA adducts were tested by the
previously described enzyme-linked immunosorbent assay (ELISA).
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2.3 GSNP selection
All GSNPs of XRCC4 gene were first screened from the SNPdatabase (http://
asia.ensembl.org/Homo_sapiens/Gene/Variation_Gene/Table?db=core;g=
ENSG00000152422;r=5:83077498-83353787). According to the data from
SNPdatabase, a total of 143 GSNPs can result in missense mutations and the
change of amino acids in XRCC4 protein, and thus they were ultimately selected
for final analyses.
2.4 Genotypic analyses
Genomic DNA in all tumor tissue samples with HCC was standard phenol-
chloroform extraction binding with proteinase K. The GSNPs of XRCC4 were
genotyped using SNaPshot method (Applied Biosystems [ABI], Foster City, CA) as
previously described [28]. For quality control, all laboratory personnel were blind
to the status of every sample with hepatocarcinoma, and controls were also
included in each analysis.
2.5 Statistical analysis
The test for genotypic distribution of XRCC4 GSNPs among HCC cases featur-
ing different AFB1-DNA adducts was accomplished using student t-test or one-way
analysis of variance (ANOVA) test. Multiple tests were adjusted using a Bonferroni
correction, and the threshold for GSNP screening was defined as α = 3.53  104.
Kaplan-Meier survival model with log-rank test and Cox regression model (the
selection of significant varies based on forward-step method with likelihood ratio
test) was used to analyze the association between XRCC4 GSNPs and HCC out-
comes. Cumulative hazard value for the effects of XRCC4 GSNPs on the hepatic
toxicity for AFB1 and corresponding 95% confidence interval (CI) were calculated
using hazard ratio (HR) from significant multivariate Cox regression model
(including all significant variates). All statistical analyses were performed with SPSS
statistical package (Version 18, SPSS Institute, Chicago, IL, USA).
3. Results
3.1 The characteristics of subjects
All subjects suffered from hepatic carcinoma, and Table 1 summarized their
characteristics. The mean age of all participants was 50.74  11.55 years, and more
than 70% of them are male. For these cancer patients, 70.3% (267/380) and 26.3%
(100/380) cases featured TNM II and III stages of tumor, and they also had an
average AFB1 exposure value of 2.27  1.09 μmol/mol DNA.
3.2 XRCC4 GSNPs increased AFB1-DNA adducts
A total of 143 GSNPs in the coding regions of XRCC4 gene were selected in our
final analyses, and Table 2 showed the genotypic distribution of all GSNPs. To
evaluate the effects of these potential GSNPs on AFB1-DNA adducts, the role of
each GSNP in the coding regions of XRCC4 gene was tested using Student t-test or
ANOVA test with the adjustment of multiple test. Among these GSNPs, only
rs1237462915 (cat#SNP016, at codon 38), rs28383151 (cat#SNP026, at codon 56),
rs762419679 (cat#SNP069, at codon 127), rs766287987 (cat#SNP112, at codon 203),
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and rs3734091 (cat#SNP138, at codon 247) significantly affected the levels of
AFB1-DNA adducts in the tumor tissues with HCC. The adduct amounts of their
wild genotypes (defined as XX genotype) were 2.15  0.97 μmol/mol DNA,
2.07  0.99 μmol/mol DNA, 2.12  0.86 μmol/mol DNA, 2.11  0.89 μmol/mol
DNA, and 2.09  0.97 μmol/mol DNA, respectively. For their mutant heterozygotic
genotypes (defined as XY genotype), the amounts of AFB-DNA adduct were from
2.64 to 4.33 μmol/mol DNA, whereas the adduct levels were from 3.04 to 5.78 for
the mutant homozygotic genotypes (defined as YY genotype) (Table 2).
Additionally, mutant genotypes of several other GSNPs, including rs761695470
(SNP008, at codon 18), rs758779099 (SNP018, at codon 40), rs144653114
(SNP054, at codon 103), rs1277864722 (SNP085, at codon 153), and rs777195630
(SNP100, at codon 180), also increased the amounts of AFB1-DNA adducts;
however, they had no statistical significance according to screening threshold value.
3.3 XRCC4 GSNPs modified the AFB1-related HCC prognosis
Because the poor prognosis of patients with HCC has been associated with the
toxicity of AFB1, we followed up the survival information of all patients and
explored whether positive GSNPs of XRCC4 modified HCC outcomes, including
overall survival (OS) and disease recurrence-free survival (RFS) (Figures 1 and 2).
Results from Kaplan-Meier survival model (based on the cumulative risk models)
and Cox regression model analyses showed that compared with their wild
n %
Total 380 100.0
Age (years)
≤35 53 13.9
36–40 38 10.0
41–45 55 14.5
46–50 43 11.3
51–55 56 14.7
56–60 42 11.1
61–65 49 12.9
≥66 44 11.6
Gender
Male 271 71.3
Female 109 28.7
Race
Han 221 58.2
Zhuang 159 41.8
TNM stage
I–II 13 3.4
III 267 70.3
IV 100 26.3
Table 1.
The characteristics of subjects.
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No. SNP ID Chr: bp Alleles
(x/y)a
Genotypes
(xx/xy/yy)b
Amino acid
position
Amino acid
change
Nxx/xy/yy
c Adducts (mean  SD) Pd
SNP001 rs142575170 5:83104923 G/A GG/GA/AA 2 E/K 323/54/3 2.28  1.09/2.21  1.08/
2.36  1.05
0.23
SNP002 rs1449631425 5:83104929 A/G AA/AG/GG 4 K/E 377/3/0 2.27  1.09/2.21  0.54/ 0.99
SNP003 rs1166890864 5:83104930 A/G AA/AG/GG 4 K/R 378/2/0 2.27  1.09/1.57  0.03/ 0.99
SNP004 rs1425642930 5:83104933 T/G TT/TG/GG 5 I/R 376/4/0 2.27  1.09/2.10  0.61/ 0.96
SNP005 rs1252823908 5:83104946 C/A CC/CA/AA 9 H/Q 376/4/0 2.27  1.09/2.16  0.56/ 0.94
SNP006 rs28383138 5:83104954 C/G CC//CG/GG 12 S/C 319/47/14 2.26  1.09/2.41  1.06/
2.00  1.07
0.23
SNP007 rs774071130 5:83104966 T/C TT/TC/CC 16 I/T 370/10/0 2.28  1.09/2.05  0.94/ 0.99
SNP008 rs761695470 5:83104971 C/T CC/CT/TT 18 H/Y 371/6/3 2.24  1.03/2.87  2.00/
4.42  2.93
0.04
SNP009 rs755776572 5:83104983 G/A GG/GA/AA 22 V/I 380/0/0 2.27  1.09// —
SNP010 rs1271180927 5:83104986 T/A TT/TA/AA 23 S/T 364/13/3 2.26  1.09/2.52  1.04/
2.44  0.77
0.89
SNP011 rs1288681786 5:83104992 G/A GG/GA/AA 25 E/K 354/26/0 2.28  1.10/2.16  0.96/ 0.56
SNP012 rs550773308 5:83104999 C/T CC/CT/TT 27 T/I 367/13/0 2.26  1.06/2.51  1.80/ 0.63
SNP013 rs1484250582 5:83105006 A/C AA/AC/CC 29 E/D 376/4/0 2.27  1.09/2.18  1.42/ 0.87
SNP014 rs1305679408 5:83105013 T/A TT/TA/AA 32 F/I 350/30/0 2.27  1.08/2.26  1.14/ 0.96
SNP015 rs1232077487 5:83105022 A/G AA/AG/GG 35 T/A 380/0/0 2.27  1.09// —
SNP016 rs1237462915 5:83105031 G/T GG/GT/TT 38 D/Y 352/19/9 2.15  0.97/3.62  1.40/
4.21  0.93
2.96  105
SNP017 rs748540743 5:83105032 A/T AA/AT/TT 38 D/V 380/0/0 2.27  1.09// —
SNP018 rs758779099 5:83105039 T/G TT/TG/GG 40 H/Q 353/25/2 2.23  1.03/2.78  1.61/
2.63  0.01
0.04
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No. SNP ID Chr: bp Alleles
(x/y)a
Genotypes
(xx/xy/yy)b
Amino acid
position
Amino acid
change
Nxx/xy/yy
c Adducts (mean  SD) Pd
SNP019 rs587779351 5:83105046 T/C TT/TC/CC 43 W/R 380/0/0 2.27  1.09// —
SNP020 rs771111816 5:83105050 C/T CC/CT/TT 44 T/I 362/25/3 2.26  1.08/2.33  1.23/
2.68  0.07
0.78
SNP021 rs1460004120 5:83105053 G/C GG/GC/CC 45 G/A 375/5/0 2.27  1.09/2.21  0.82/ 0.91
SNP022 rs1248835327 5:83111031 C/T CC/CT/TT 48 S/F 370/10/0 2.27  1.09/2.21  1.01/ 0.87
SNP023 rs1326359694 5:83111033 G/A GG/GA/AA 49 E/K 355/25/0 2.28  1.11/2.16  0.76/ 0.61
SNP024 rs868207005 5:83111039 G/A GG/GA/AA 51 E/K 380/0/0 2.27  1.09// —
SNP025 rs945155269 5:83111049 A/C AA/AC/CC 54 Q/P 364/26/0 2.29  1.07/2.02  1.04/ 0.24
SNP026 rs28383151 5:83111054 G/A GG/GA/AA 56 A/T 277/63/40 2.07  0.99/2.64  1.33/
3.04  0.78
2.83  1055
SNP027 rs1245127767 5:83111063 A/G AA/AG/GG 59 M/V 354/25/1 2.27  1.10/2.18  0.92/2.78* 0.67*
SNP028 rs748124509 5:83111066 G/T GG/GT/TT 60 A/S 354/23/3 2.25  1.11/2.36  0.74/2.78  1.01 0.66
SNP029 rs760546308 5:83111070 T/C TT/TC/CC 61 M/T 352/28/0 2.27  1.04/2.25  1.56/ 0.91
SNP030 rs1369565470 5:83111071 G/C GG/GC/CC 61 M/I 380/0/0 2.27  1.09// —
SNP031 rs867574505 5:83111072 G/A GG/GA/AA 62 E/K 380/0/0 2.27  1.09// —
SNP032 rs1285557699 5:83111073 A/G AA/AG/GG 62 E/G 380/0/0 2.27  1.09// —
SNP033 rs1248297453 5:83111085 A/G AA/AG/GG 66 Y/C 351/29/0 2.26  1.07/2.36  1.25/ 0.63
SNP034 rs776362814 5:83111087 G/A GG/GA/AA 67 V/I 350/30/0 2.26  1.11/2.31  0.84/ 0.83
SNP035 rs1423928075 5:83111090 G/A GG/GA/AA 68 G/S 380/0/0 2.27  1.09// —
SNP036 rs1478505961 5:83111093 G/A GG/GA/AA 69 E/K 250/28/2 2.27  1.07/2.24  1.28/2.69  1.16 0.86
SNP037 rs759064378 5:83111097 T/C TT/TC/CC 70 L/P 354/26/0 2.28  1.09/2.15  1.01/ 0.58
SNP038 rs371307071 5:83111100 G/C GG/GC/CC 71 R/T 380/0/0 2.27  1.09// —
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No. SNP ID Chr: bp Alleles
(x/y)a
Genotypes
(xx/xy/yy)b
Amino acid
position
Amino acid
change
Nxx/xy/yy
c Adducts (mean  SD) Pd
SNP039 rs61762970 5:83111112 T/C TT/TC/CC 75 L/S 356/24/0 2.29  1.10/1.99  0.89/ 0.20
SNP040 rs763501478 5:83111117 G/A GG/GA/AA 77 G/R 361/29/0 2.27  1.09// —
SNP041 rs764572419 5:83111120 G/T GG/GT/TT 78 A/S 349/31/0 2.26  1.09/2.39  1.09/ 0.52
SNP042 rs528259464 5:83111121 C/T CC/CT/TT 78 A/V 376/4/0 2.26  1.09/2.77  0.44/ 0.36
SNP043 rs757644947 5:83111126 C/T CC/CT/TT 80 P/S 369/11/0 2.26  1.07/2.51  1.51/ 0.46
SNP044 rs572613361 5:83111138 T/C TT/TC/CC 84 Y/H 351/27/2 2.27  /2.24  1.02/3.09  0.47 0.57
SNP045 rs1398927737 5:83111141 A/C AA/AC/CC 85 T/P 380/0/0 2.27  1.09// —
SNP046 rs756247552 5:83111142 C/T CC/CT/TT 85 T/M 374/6/0 2.26  1.08/2.56  1.35/ 0.50
SNP047 rs149355996 5:83111147 A/T AA/AT/TT 87 N/Y 371/9/0 2.27  1.10/2.36  0.70/ 0.81
SNP048 rs1049631686 5:83111162 T/A TT/TA/AA 92 S/T 364/26/0 2.27  1.09// —
SNP049 rs772190420 5:83111169 A/G AA/AG/GG 94 Y/C 354/26/0 2.28  1.08/2.08  1.23/ 0.36
SNP050 rs1239084198 5:83111171 T/G TT/TG/GG 95 F/V 356/24/0 2.26  1.07/2.36  1.34/ 0.68
SNP051 rs1184763400 5:83111174 T/A TT/TA/AA 96 F/I 380/0/0 2.27  1.09// —
SNP052 rs1236326383 5:83111177 T/C TT/TC/CC 97 F/L 366/14/0 2.28  1.09/1.92  0.92/ 0.24
SNP053 rs1472843465 5:83111180 G/A GG/GA/AA 98 E/K 377/3/0 2.27  1.09/2.58  0.84/ 0.63
SNP054 rs144653114 5:83111195 G/A GG/GA/AA 103 N/D 240/127/
13
2.17  1.09/2.48  1.08/
2.11  0.84
0.03
SNP055 rs79561451 5:83195782 T/C TT/TC/CC 110 S/P 352/25/3 2.28  1.11/2.20  0.84/
1.82  0.37
0.74
SNP056 rs757113391 5:83195787 C/G CC//CG/GG 111 F/L 380/0/0 2.27  1.09// —
SNP057 rs1378785946 5:83195794 G/C GG/GC/CC 114 E/Q 360/20/0 2.277  1.10/2.227  0.84/ 0.83
SNP058 rs1240771489 5:83195795 A/G AA/AG/GG 114 E/G 281/80/19 2.297  1.09/2.197  1.06/ 0.75
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No. SNP ID Chr: bp Alleles
(x/y)a
Genotypes
(xx/xy/yy)b
Amino acid
position
Amino acid
change
Nxx/xy/yy
c Adducts (mean  SD) Pd
SNP059 rs769556494 5:83195797 A/G AA/AG/GG 115 K/E 340/40/0 2.277  1.09/2.277  1.04/ 0.99
SNP060 rs1056939125 5:83195798 A/C AA/AC/CC 115 K/T 380/0/0 2.27  1.09// —
SNP061 rs1301137729 5:83195800 G/C GG/GC/CC 116 V/L 359/21/0 2.27  1.09/2.19  0.99/ 0.74
SNP062 rs550178738 5:83195807 A/T AA/AT/TT 118 N/I 341/39/0 2.27  1.10/2.28  1.00/ 0.93
SNP063 rs375157105 5:83195809 C/A CC/CA/AA 119 P/T 352/28/0 2.29  1.102.06  0.83/ 0.28
SNP064 rs768175717 5:83195810 C/T CC/CT/TT 119 P/L 380/0/0 2.27  1.09// —
SNP065 rs369641536 5:83195816 A/G AA/AG/GG 121 E/G 380/0/0 2.27  1.09// —
SNP066 rs1395194011 5:83195819 T/A TT/TA/AA 122 V/D 289/81/10 2.24  1.07/2.62  1.22/ 0.05
SNP067 rs1198491910 5:83195821 A/G AA/AG/GG 123 I/V 348/32/0 2.27  1.09/2.25  1.13/ 0.95
SNP068 rs1159852376 5:83195824 A/G AA/AG/GG 124 R/G 369/11/0 2.26  1.10/2.40  0.88/ 0.64
SNP069 rs762419679 5:83195834 T/C TT/TC/CC 127 I/T 359/15/6 2.12 0.86/4.33 1.99/5.99 1.12 1.17  1043
SNP070 rs1412506484 5:83195840 A/G AA/AG/GG 129 Y/C 349/31/0 2.27  1.10/2.26  1.32/ 0.96
SNP071 rs1178870682 5:83195848 G/C GG/GC/CC 132 D/H 365/15/0 2.27  1.10/2.26  0.78/ 0.98
SNP072 rs1484047716 5:83195852 C/G CC//CG/GG 133 T/S 374/6/0 2.26  1.07/2.71  1.90/ 0.32
SNP073 rs28360135 5:83195855 T/C TT/TC/CC 134 I/T 304/64/12 2.31  1.13/2.12  0.90/
2.12  0.69
0.39
SNP074 rs1335801774 5:83195856 T/G TT/TG/GG 134 I/M 380/0/0 2.27  1.09// —
SNP075 rs372774793 5:83195857 G/C GG/GC/CC 135 A/P 358/22/0 2.27  1.06/2.25  1.46/ 0.92
SNP076 rs1384832919 5:83195863 A/G AA/AG/GG 137 N/D 368/12/0 2.27  1.10/2.00  0.59/ 0.38
SNP077 rs56334522 5:83195865 T/G TT/TG/GG 137 N/K 366/13/1 2.26  1.10/2.53  0.80/1.34b 0.89
SNP078 rs370037164 5:83195869 G/A GG/GA/AA 139 A/T 292/84/4 2.28  1.06/2.23  1.18/
2.49  0.83
0.89
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No. SNP ID Chr: bp Alleles
(x/y)a
Genotypes
(xx/xy/yy)b
Amino acid
position
Amino acid
change
Nxx/xy/yy
c Adducts (mean  SD) Pd
SNP079 rs374892515 5:83195876 A/G AA/AG/GG 141 N/S 380/0/0 2.27  1.09// —
SNP080 rs28360136 5:83195878 G/C GG/GC/CC 142 E/Q 254/111/
15
2.33  1.10/2.12  1.02/2.35  1.26 0.21
SNP081 rs553111266 5:83195883 C/A CC/CA/AA 143 H/Q 373/7/0 2.26  1.09/2.75  1.07/ 0.24
SNP082 rs1022211508 5:83195897 A/G AA/AG/GG 148 N/S 342/38/0 2.30  1.11/2.03  0.79/ 0.15
SNP083 rs757278630 5:83195903 G/A GG/GA/AA 150 R/K 378/12/0 2.27  1.09/1.99  1.01/ 0.36
SNP084 rs1375107569 5:83195905 C/T CC/CT/TT 151 L/F 380/0/0 2.27  1.09// —
SNP085 rs1277864722 5:83195912 G/A GG/GA/AA 153 R/K 355/25/0 2.29  1.01/1.93  0.72/ 0.02
SNP086 rs745751715 5:83195922 T/G TT/TG/GG 156 N/K 289/89/2 2.28  1.04/2.25  1.23/2.12  1.83 0.97
SNP087 rs1201811742 5:83195924 A/C AA/AC/CC 157 D/A 353/26/1 2.24  1.07/2.67  1.22/2.72e 0.13
SNP088 rs369499884 5:83195930 A/G AA/AG/GG 159 Q/R 367/13/0 2.28  1.09/2.03  1.08/ 0.42
SNP089 rs372493882 5:83195933 G/T GG/GT/TT 160 G/V 250/30/0 2.29  1.10/2.07  0.97/ 0.30
SNP090 rs1156689163 5:83203553 T/G TT/TG/GG 162 F/V 380/0/0 2.27  1.09// —
SNP091 rs1325151692 5:83203554 T/A TT/TA/AA 162 F/Y 345/95/0 2.26  1.04/2.39  1.46/ 0.49
SNP092 rs375731584 5:83203566 T/G TT/TG/GG 166 V/G 355/25/0 2.25  1.09/2.48  0.97/ 0.32
SNP093 rs1359488275 5:83203568 A/T AA/AT/TT 167 S/C 380/0/0 2.27  1.09// —
SNP094 rs753605351 5:83203575 A/C AA/AC/CC 169 K/T 385/15/0 2.26  1.10/2.40  0.89/ 0.64
SNP095 rs1376295451 5:83203587 A/T AA/AT/TT 173 E/V 340/40/0 2.28  1.10/2.18  0.98/ 0.58
SNP096 rs778422015 5:83203595 C/T CC/CT/TT 176 L/F 380/0/0 2.27  1.09// —
SNP097 rs777300742 5:83203599 A/G AA/AG/GG 177 Y/C 354/26/0 2.26  1.08/2.39  1.24/ 0.57
SNP098 rs140143447 5:83203604 C/T CC/CT/TT 179 R/W 372/8/0 2.28  1.09/1.69  0.56/ 0.13
SNP099 rs771544881 5:83203605 G/A GG/GA/AA 179 R/Q 380/0/0 2.27  1.09// —
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No. SNP ID Chr: bp Alleles
(x/y)a
Genotypes
(xx/xy/yy)b
Amino acid
position
Amino acid
change
Nxx/xy/yy
c Adducts (mean  SD) Pd
SNP100 rs777195630 5:83203607 T/C TT/TC/CC 180 F/L 354/26/0 2.22  1.04/2.89  1.51/ 0.04
SNP101 rs1379408635 5:83203610 A/T AA/AT/TT 181 I/F 338/41/1 2.26  1.07/2.37  1.22/2.98e 0.67
SNP102 rs1199884817 5:83203611 T/C TT/TC/CC 181 I/T 345/35/ 2.27  1.08/2.26  1.20/ 0.96
SNP103 rs1018879495 5:83203623 A/T AA/AT/TT 185 N/I 366/14/0 2.27  1.09/2.18  0.94/ 0.76
SNP104 rs1482288279 5:83203635 C/T CC/CT/TT 189 T/I 380/0/0 2.27  1.09// —
SNP105 rs770217916 5:83203641 T/A TT/TA/AA 191 I/N 341/38/1 2.28  1.10/2.10  0.90/4.31b 0.11
SNP106 rs775587299 5:83203644 G/T GG/GT/TT 192 R/I 351/24/5 2.28  1.09/2.24  1.16/
1.94  0.64
0.79
SNP107 rs763186148 5:83203652 C/T CC/CT/TT 195 H/Y 328/50/2 2.28 1.11/2.23  0.97/2.18 0.47 0.95
SNP108 rs1173748737 5:83203653 A/G AA/AG/GG 195 H/R 380/0/0 2.27  1.09// —
SNP109 rs764109844 5:83203654 T/G TT/TG/GG 195 H/Q 380/0/0 2.27  1.09// —
SNP110 rs1458486332 5:83203659 A/G AA/AG/GG 197 K/R 380/0/0 2.27  1.09// —
SNP111 rs1263079073 5:83203676 C/G CC//CG/GG 203 Q/E 355/25/ 2.28  1.09/2.18  1.09/ 0.69
SNP112 rs766287987 5:83203678 A/T AA/AT/TT 203 Q/H 357/16/7 2.11  0.89/4.15  0.77/5.78  1.17 1.05  1059
SNP113 rs778723397 5:83203683 G/A GG/GA/AA 205 R/Q 365/15/0 2.29  1.09/1.87  0.97/ 0.15
SNP114 rs777199609 5:83203691 G/C GG/GC/CC 208 D/H 292/86/2 2.22  1.05/2.43  1.18/
2.86  1.40
0.20
SNP115 rs1224705261 5:83203694 A/G AA/AG/GG 209 I/V 380/0/0 2.27  1.09// —
SNP116 rs201604424 5:83203698 A/G AA/AG/GG 210 K/R 300/72/8 2.29  1.11/2.15  0.97/2.77  1.03 0.26
SNP117 rs1276157833 5:83203701 A/G AA/AG/GG 211 Q/R 371/9/0 2.28  1.08/1.82  1.17/ 0.22
SNP118 rs1298401873 5:83203706 G/A GG/GA/AA 213 G/R 359/21/0 2.29  1.10/1.93  0.87/ 0.14
SNP119 rs746407658 5:83204816 G/A GG/GA/AA 214 E/K 291/79/10 2.30  1.10/2.22  1.09/1.72  072 0.23
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No. SNP ID Chr: bp Alleles
(x/y)a
Genotypes
(xx/xy/yy)b
Amino acid
position
Amino acid
change
Nxx/xy/yy
c Adducts (mean  SD) Pd
SNP120 rs969467594 5:83204820 C/G CC//CG/GG 215 T/S 380/0/0 2.27  1.09// —
SNP121 rs780330653 5:83204823 C/A CC/CA/AA 216 A/E 307/61/12 2.24  1.08/2.46  1.19/
2.06  0.72
0.28
SNP122 rs1348464342 5:83204825 A/G AA/AG/GG 217 I/V 375/5/0 2.27  1.09/2.46  0.94/ 0.69
SNP123 rs749647860 5:83204828 T/G TT/TG/GG 218 C/G 358/22/0 2.27  1.08/2.22  1.23/ 0.84
SNP124 rs908326126 5:83204840 A/G AA/AG/GG 222 T/A 380/0/0 2.27  1.09// —
SNP125 rs1347664669 5:83204847 A/G AA/AG/GG 224 D/G 354/26/0 2.26  1.09/2.38  1.12/ 0.58
SNP126 rs866477694 5:83204848 C/A CC/CA/AA 224 D/E 380/0/0 2.27  1.09// —
SNP127 rs774555675 5:83204850 G/A GG/GA/AA 225 R/Q 348/32/0 2.28  1.10/2.11  0.97/ 0.39
SNP128 rs748307585 5:83204852 G/A GG/GA/AA 226 D/N 285/86/9 2.29 1.09/2.20 1.09/2.37 1.12 0.77
SNP129 rs368106955 5:83204867 G/A GG/GA/AA 231 E/K 380/0/0 2.27  1.09// —
SNP130 rs140579916 5:83204874 C/A CC/CA/AA 233 T/N 342/38/0 2.26 1.07/2.39  1.23/2.27  1.09 0.46
SNP131 rs762812825 5:83204882 G/A GG/GA/AA 236 E/K 357/21/2 2.26  1.08/2.43  1.33/
2.23  0.26
0.78
SNP132 rs574436773 5:83204897 A/T AA/AT/TT 241 T/S 376/4/0 2.27  1.09/1.96  1.19/ 0.57
SNP133 rs542187236 5:83204901 A/G AA/AG/GG 242 D/G 380/0/0 2.27  1.09// —
SNP134 rs1013137284 5:83204904 T/A TT/TA/AA 243 L/H 374/6/0 2.26  1.09/3.00  0.56/ 0.10
SNP135 rs1261641487 5:83204906 T/C TT/TC/CC 244 S/P 380/0/0 2.27  1.09// —
SNP136 rs767176080 5:83204907 C/T CC/CT/TT 244 S/F 376/6/0 2.27  1.09/1.71  0.34/ 0.31
SNP137 rs371824973 5:83204910 G/A GG/GA/AA 245 G/E 380/0/0 2.27  1.09// —
SNP138 rs3734091 5:83204915 G/T GG/GT/TT 247 A/S 296/46/38 2.09  0.97/2.79  1.49/
3.08  0.77
1.20  1070
SNP139 rs141122119 5:83258556 A/G AA/AG/GG 258 I/V 363/17/0 2.28  1.10/2.04  0.82/ 0.37
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SNP140 rs138837678 5:83258665 A/C AA/AC/CC 294 Q/P 372/8/0 2.28  1.09/1.98  0.79/ 0.45
SNP141 rs61749611 5:83353207 A/C AA/AC/CC 324 N/H 348/30/2 2.27  1.09/2.21  1.14/2.53  0.16 0.90
SNP142 rs148273490 5:83353231 G/C GG/GC/CC 332 D/H 356/24/0 2.29  1.10/2.02  0.86/ 0.25
SNP143 rs141304949 5:83353238 T/C TT/TC/CC 334 I/T 344/35/1 2.26  1.07/2.39  1.26/1.37e 0.58
ax/y represents wild-type allele/ variant type allele.
bxx/xy/yy represents wild-type homozygote/heterozygote/variant-type homozygote.
cNxx/xy/yy represents the number of subjects with xx genotype, the number of subjects with xy genotype, and the number of subjects with yy genotype.
dP values are calculated using t-test or one-way analysis of variance.
eSD is not determined.
* SD for genotype yy is not determined and P-value is used for genotypes xx and xy.
Table 2.
The association between SNPs in the coding region of XRCC4 and AFB1-DNA adducts in tissues with hepatocellular carcinoma.
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Figure 1.
XRCC4 GSNPs significantly correlating with the overall survival (OS) of hepatocellular carcinoma (HCC).
Cumulative hazard function was plotted by Kaplan-Meier methodology, and P value was calculated with two-
sided log-rank tests. The relative hazard ratio (HR) values for genotypes were calculated using multivariable
Cox regression models (with all significant variables) based on forward-step method with likelihood ratio test.
Figure 2.
XRCC4 GSNPs significantly correlating with the disease recurrence-free survival (RFS) of hepatocellular
carcinoma (HCC). Cumulative hazard function was plotted by Kaplan-Meier methodology, and P value was
calculated with two-sided log-rank tests. The relative hazard ratio (HR) values for genotypes were calculated
using multivariable Cox regression models (with all significant variables) based on forward-step method with
likelihood ratio test.
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genotypes (XX genotypes), the mutant genotypes (including XY and YY geno-
types) of rs28383151, rs766287987, and rs3734091 polymorphisms increased cumu-
lative hazard for OS [HR = 1.31 (1.04–1.67), 1.72 (1.09–2.71), and 1.42 (1.10–1.82),
respectively] (Figure 1). For RFS, the corresponding hazard values were 3.31 (2.33–
4.69) for rs28383151, 1.85 (1.03–3.67) for rs766287987, and 4.45 (3.13–6.34) for
rs3734091, respectively (Figure 2).
4. Discussion
In this study, we investigated the association between the GSNPs in the coding
regions of XRCC4 gene and the toxic effects of AFB1 on the liver. We found that
five XRCC4 GSNPs, including rs1237462915 (at codon 38), rs28383151 (at codon
56), rs762419679 (at codon 127), rs766287987 (at codon 203), and rs3734091 (at
codon 247), significantly increased the amount of AFB1-DNA adducts in tissues
with HCC (2.07–2.15 μmol/mol DNA for XY genotypes and 2.64–4.33 μmol/mol
DNA for YY genotypes, respectively) and progressed the cumulative hazard of
AFB1 hepatic toxicity.
AFB1 acts as a type of human chemical toxicant, and the toxic effects of this
toxicant are characterized by organophilism (mainly causing hepatic damage),
genic toxicity (mainly inducing DNA damages such as hotspot mutation at codon
249 of TP53 gene, AFB1-DNA adduct formation, and so on), and carcinogenicity
(mainly resulting in HCC) [6–8]. Among the hepatic toxicity of AFB1, the forma-
tion of AFB1-DNA adducts in hepatic cells is a key step during the metabolism of
this toxicant [9–14]. Evidence from molecular epidemiological studies and clinical
studies has proved that the levels of AFB1-DNA adducts in the hepatic tissues are
positively associated with the levels and time of AFB1 exposure [3, 24, 26–44]. This
is indicative of AFB1-DNA adduct acting as the biomarker for AFB1’s toxic capacity
in the liver. In this study, AFB1-DNA adduct in the tumor tissues with HCC was
used to evaluate hepatic toxicity related to AFB1, mainly because normal liver tissue
samples cannot be obtained. Our results exhibited HCC tumor samples from high
AFB1 exposure areas have an average adduct amount of 2.27 1.09 μmol/mol DNA.
Supporting our findings, several studies from high AFB1 exposure areas Nanning
and Tiandong, China, have also shown the similar level of DNA adducts [4, 5,
26, 27, 37, 39, 45]. Taken together, the amount of AFB1-DNA adducts should be able
to reflect the hepatic toxic potential of AFB1.
XRCC4, a key gene in the V(D)J recombination repair pathway, is located at
5q14.2 and consists of 13 exons (PubMed). Normally, XRCC4 is mainly expressed in
genital meatus, alimentary tract, and lymphoid tissue; however, its expression will
noticeably increase in other tissues such as the skin and liver under the condition of
in vitro and in vivo injuries. This gene’s encoding protein plays a vital role in both
NHEJ and the completion of V(D)J recombination via acting as a scaffold protein
for DNA ligase IV and DNA-PK in the repair of DNA DSBs [15, 19]. Mutations in
XRCC4, including GSNPs and other non-GSNPs variants, can cause endocrine
dysfunction, microcephaly, short stature, and diseases [16, 21]. With the develop-
ment of human Geno projects, more than 1000 GSNPs are identified. Among these
GSNPs, we focused on genetic alterations in the coding regions of XRCC4, mainly
because they will result in missense mutations and ultimately cause the structure
damage and function deficiency of XRCC4 protein. Molecular epidemiological
studies have displayed that the GSNPs in the XRCC4 genes can increase DNA repair
capacity and increase the risk of some tumors such as lung cancer, colon cancer,
HCC, and so on [21, 46–51]. Evidence from in vitro and in vivo studies has also
proved that XRCC4 GSNPs increase the amount of DNA damage and induce more
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gene mutations [23, 24, 26, 27]. In our study, we tested the genotypic distributions
of all known GSNPs in the coding region of XRCC4 in liver tumor tissues. Five
positive GSNPs were identified, and they result in the change of amino acid D to Y
at codon 38 for rs1237462915, A to T at codon 56 for rs28383151, I to T at codon 127
for rs762419679, Q to H at codon 203 for rs766287987, and A to S at codon 247 for
rs3734091, respectively. Although evidence that several other GSNPs, including
rs761695470, rs758779099, rs144653114, rs1277864722, and rs777195630, increased
the amounts of AFB1-DNA adducts was not statistically significant according to our
defined threshold value, their effects should not be neglected because small-size
samples may underestimate values.
Because the toxic effects of AFB1 also modify the prognosis of patients with
HCC [26, 27, 33, 52, 53], we accomplished patients’ survival analyses on the basis of
the cumulative risk models and found only rs28383151, rs766287987, and rs3734091
polymorphisms shortened HCC cases’ OS and RFS. Supporting our findings, several
previous reports have proved that XRCC4 GSNPs can alter the levels of XRCC4
mRNA and protein expression and dysregulation of XRCC4 expression increasing
the amount of AFB1-DNA adducts and mutative risk of TP53 gene [23, 24, 26, 27].
To conclude, this study is the first report investigating the modified function of
XRCC4 GSNPs on AFB1’s hepatic toxicity. Our findings suggest that the GSNPs in
the coding regions of XRCC4 gene, like rs1237462915, rs28383151, rs762419679,
rs766287987, and rs3734091, may alter the DNA repair capacity of DNA damage
induced by AFB1. If these individuals with mutant genotypes of these GSNPs
decrease their exposure to AFB1, they will be free from toxic effects of AFB1 on
hepatic damage. Several limitations should be focused for our study. First, relatively
small-size samples may underestimate the effects of XRCC4 GSNPs on AFB1
hepatic toxicity. Second, the hospital-based design may result in selective bias.
Third, we only accomplished the cumulative risk analyses but not the cumulative
survival analyses. Finally, we did not finish functional and mechanical analyses.
Thus, XRCC4 GSNPs may be valuable biomarkers for predicting the toxic effects of
AFB1 on the liver once the present findings were proved by larger samples and toxic
function analyses.
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